Auro Laboratories P/E Ratio
Current P/E Ratio
85.27
High Valuation
Very High - High growth expectations or significantly overvalued
Auro Laboratories (AUROLAB) P/E ratio is 85.27 (High), EPS (TTM) ₹5.67, current price ₹254.50 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see Auro Laboratories stock price NSE.
Current Valuation Metrics
P/E Ratio
85.27
Current Price
₹254.50
EPS (TTM)
₹5.67
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
52.63
Sector Median
29.65
Sector Rank
#11 of 194
Sector Percentile
5.7%
Earnings Breakdown (TTM)
TTM EPS
₹2.76
Sept 2025
₹1.15
Jun 2025
₹-0.17
AUROLAB P/E Ratio — Valuation Signal & Historical Context
Auro Laboratories P/E 85.27 — signal: Overvalued. Analyse AUROLAB shareholder distribution to track promoter, FII and institutional holdings.
- Stock appears overvalued with PE of 85.27, suggesting caution for new investments
- Trading at premium to sector average PE of 52.63
AUROLAB vs Healthcare Peers — P/E Ratio Comparison
Auro Laboratories P/E 85.27 vs Healthcare average 52.63, median 29.65 — range 2.86–850.0.
Sector Average
52.63
Sector Median
29.65
Lowest P/E
2.86
Highest P/E
850.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.64 | ₹29 | Low |
| Phaarmasia | PHRMASI | 4.06 | ₹68 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.97 | ₹7,724 | Low |
| Shelter Pharma | SHELTER | 5.45 | ₹48 | Low |
| Mono Pharmacare | MONOPHARMA | 6.51 | ₹20 | Low |
| Amwill Health Care | AMWILL | 7.33 | ₹78 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹71 | Low |
| Brooks Laboratories | BROOKS | 8.06 | ₹206 | Low |
| Royal Sense | ROYAL | 8.08 | ₹62 | Low |